Insulet Corp.'s (PODD) groundbreaking Omnipod 5 Automated Insulin Delivery ("AID") system (Omnipod 5) received the FDA's approval for use by type 2 diabetes patients (ages 18 years and above). The news comes after the company submitted 510(k) for an expanded indication of Omnipod 5 to the FDA, in June 2024, based on the favorable clinical outcomes of the SECURE-T2D pivotal trial. With this development, Omnipod 5 is the first and only AID system indicated for both type 1 and type 2 diabetes. Insulet's Robust ...